Huntington’s disease is an inherited condition that gradually breaks down nerve cells in the brain, affecting movement, thinking, and emotions over many years. It is passed down through families in a clear pattern, and a single well-understood genetic change is responsible, which means a blood test can confirm the diagnosis and even identify the condition before symptoms begin. While there is no cure yet and the disease is progressive, treatments can ease specific symptoms, supportive care makes a real difference to quality of life, and research into therapies that target the underlying genetic cause is advancing quickly. This guide explains what Huntington’s disease is, the symptoms across its three main areas, how it is inherited and diagnosed, the treatments available today, and the latest scientific progress.
What is Huntington’s disease?
Huntington’s disease is a progressive neurodegenerative disorder, meaning it causes certain brain cells to deteriorate and die over time. The damage centers on regions deep in the brain that coordinate movement, thought, and mood, which is why the condition produces such a wide mix of physical, cognitive, and emotional symptoms. It is caused by a change in a single gene, and everyone who inherits that change and lives long enough will eventually develop the disease.
Symptoms most often begin between the ages of 30 and 50, though a rarer juvenile form can appear before age 20 and tends to progress faster. Huntington’s disease is uncommon, affecting an estimated 13 to 15 people per 100,000 in the United States, with more than 15,000 Americans living with it and many more at risk because a parent carries the gene. After symptoms start, the disease typically progresses over 15 to 20 years, and it is not contagious in any way.
Symptoms of Huntington’s disease
Huntington’s disease affects three broad areas, and symptoms in each can appear in any order, sometimes years apart. The psychiatric and cognitive changes are often the earliest and can be mistaken for other conditions before the movement symptoms make the picture clearer.
| Area affected | Common symptoms |
|---|---|
| Movement | Involuntary jerking or writhing movements called chorea, muscle rigidity, abnormal eye movements, and trouble with speech and swallowing |
| Thinking | Difficulty planning and organizing, trouble focusing, slowed thinking, and, over time, memory problems that can progress to dementia |
| Mood and behavior | Depression, irritability, apathy, anxiety, and social withdrawal, often among the first changes to appear |
The most recognizable symptom is chorea, a pattern of involuntary, dance-like movements that can affect the face, arms, legs, and trunk. As the disease advances, movement problems can shift toward stiffness and slowness, and difficulty with swallowing and balance raises the risk of complications such as pneumonia and falls. Because depression and mood changes are common and the disease carries an increased risk of suicidal thoughts, emotional support and regular mental health care are an important part of managing Huntington’s disease, and anyone experiencing thoughts of self-harm should reach out to a clinician or a crisis line for help.
What causes Huntington’s disease?
Huntington’s disease is caused by a change in the HTT gene, which carries instructions for a protein called huntingtin. The specific change is an expanded section of DNA in which three building blocks, cytosine, adenine, and guanine, repeat too many times, known as a CAG repeat expansion. The abnormally long protein that results gradually damages and kills brain cells.
The condition follows an autosomal dominant inheritance pattern, which means a person needs only one copy of the altered gene to develop the disease, and each child of an affected parent has a 50 percent chance of inheriting it. The number of CAG repeats also tends to grow from one generation to the next, a phenomenon called anticipation that can lead to earlier onset in children than in their parents. Because the cause is a single inherited gene, family history is central to understanding an individual’s risk.
How Huntington’s disease is diagnosed
Diagnosis combines a neurological and psychiatric exam, a detailed family history, and a genetic blood test that counts the number of CAG repeats in the HTT gene. Brain imaging such as MRI can show shrinkage in the movement-control regions and helps support the picture, but the genetic test is what confirms the diagnosis. The repeat count also carries meaning on its own, as summarized below.
| CAG repeat count | What it means |
|---|---|
| 26 or fewer | Normal; the person will not develop Huntington’s disease |
| 27 to 35 | Intermediate; no symptoms expected, but the repeat may expand in children |
| 36 to 39 | Reduced penetrance; symptoms may or may not develop, often later and milder |
| 40 or more | Full penetrance; the person will develop the disease within a normal lifespan |
People at risk who have no symptoms can choose predictive testing to learn whether they carry the gene, a decision that is always paired with genetic counseling because of its deep personal, family, and emotional implications. Researchers are also studying blood-based markers of nerve damage, such as neurofilament light chain, to track how the disease progresses, though these do not replace genetic testing for diagnosis. Learning how to read the flags and reference ranges on a lab report can help you understand what these various tests measure.
Treatment options for Huntington’s disease
There is no treatment yet that stops or reverses Huntington’s disease, so current care focuses on relieving symptoms, supporting function, and maintaining quality of life. A team that may include neurologists, psychiatrists, physical and occupational therapists, speech therapists, and social workers tailors care to each person’s needs.
| Symptom target | Common approaches |
|---|---|
| Chorea | Medicines called VMAT2 inhibitors, including tetrabenazine, deutetrabenazine, and valbenazine |
| Mood and behavior | Antidepressants, mood stabilizers, and other psychiatric medicines, plus counseling |
| Daily function | Physical, occupational, and speech therapy to support movement, independence, and swallowing |
| Nutrition and safety | Higher-calorie diets, swallowing strategies, and home changes to reduce fall risk |
For the involuntary movements of chorea, a class of drugs known as VMAT2 inhibitors can help, and one of them, valbenazine, was approved specifically for Huntington’s chorea in 2023. Managing depression, irritability, and other mood symptoms with medication and counseling is equally important, both for well-being and for safety. Physical, occupational, and speech therapy help people stay active and independent for as long as possible, while attention to nutrition, swallowing, and a safe home environment addresses some of the most serious complications of advanced disease.
Living with Huntington’s disease and long-term outlook
Huntington’s disease progresses gradually over one to three decades, and while the course cannot yet be changed, thoughtful care can meaningfully improve daily life at every stage. Regular follow-up allows symptoms to be treated as they emerge, and a strong support network, including specialized clinics and patient organizations, helps families plan for changing needs. Many people remain engaged in work, relationships, and activities they value well into the disease.
Because Huntington’s disease affects mood and thinking as much as movement, mental health support is central rather than optional, and caregivers benefit from support too. As the disease advances, care shifts toward maintaining comfort, nutrition, and safety, and toward honoring the person’s wishes through advance planning. Comparing its cognitive changes with those of other conditions, such as the memory and thinking decline of dementia, can help families understand what to expect and what support is available.
Latest scientific advances in Huntington’s disease research
Huntington’s disease research is advancing on two fronts: better control of symptoms and, for the first time, therapies aimed at the genetic root of the disease. According to PubMed-indexed research, the pivotal KINECT-HD trial published in Lancet Neurology in 2023 showed that valbenazine substantially reduced chorea compared with placebo over 12 weeks and was generally well tolerated, providing the evidence behind its approval for Huntington’s chorea (Furr Stimming et al., 2023). What this means for you: people troubled by involuntary movements now have a well-studied, once-daily option that can make daily activities easier.
On the disease-modifying front, a 2023 analysis in the New England Journal of Medicine re-examined the halted trial of tominersen, a drug designed to lower the harmful huntingtin protein, and found a possible benefit in younger patients with earlier-stage disease, which is now being tested in a new trial (McColgan et al., 2023). What this means for you: although the first large trial did not succeed, the effort to switch off the disease at its source continues, and treatment timing may prove important. Looking ahead to earlier detection, a 2026 study in the Journal of Neural Transmission found that simple measures of speech and language, combined with a blood marker of nerve damage, could predict meaningful decline (Puig-Davi et al., 2026). What this means for you: low-cost tools like a speech recording plus a blood test may eventually help doctors identify who is progressing faster and would benefit most from emerging treatments.
Glossary of key Huntington’s disease terms
| Term | Definition |
|---|---|
| HTT gene | The gene that carries instructions for the huntingtin protein; its expansion causes Huntington’s disease. |
| CAG repeat | A stretch of repeating DNA letters in the HTT gene; too many repeats cause disease. |
| Chorea | Involuntary, irregular, dance-like movements, a hallmark of Huntington’s disease. |
| Autosomal dominant | An inheritance pattern in which one altered gene copy is enough to cause the condition. |
| Anticipation | The tendency for the repeat to expand and symptoms to appear earlier in later generations. |
| Predictive testing | A genetic test that tells an at-risk, symptom-free person whether they carry the gene. |
| VMAT2 inhibitor | A class of medicine used to reduce the involuntary movements of chorea. |
Frequently asked questions about Huntington’s disease
What is Huntington’s disease and what causes it?
Huntington’s disease is an inherited, progressive brain disorder that affects movement, thinking, and mood. It is caused by an expanded CAG repeat in the HTT gene, which produces an abnormal protein that gradually damages brain cells. Symptoms usually begin in mid-adulthood and worsen over time.
What are the first signs of Huntington’s disease?
Early signs are often subtle and can include mood and personality changes such as depression, irritability, or apathy, along with trouble organizing tasks or concentrating. Small involuntary movements may appear before the more obvious chorea develops. Because early symptoms overlap with other conditions, diagnosis can take time without genetic testing.
Is Huntington’s disease dominant or recessive, and what are the odds of passing it on?
Huntington’s disease is autosomal dominant, so only one copy of the altered gene is needed to cause it. Each child of a parent who carries the gene has a 50 percent chance of inheriting it. The repeat can also lengthen between generations, sometimes leading to earlier onset in children.
How is Huntington’s disease diagnosed, and what does the genetic test involve?
Diagnosis uses a neurological and psychiatric exam, family history, and a genetic blood test that counts the CAG repeats in the HTT gene. Brain imaging can support the diagnosis. At-risk people without symptoms can also choose predictive testing, always alongside genetic counseling.
How many CAG repeats indicate Huntington’s disease?
A count of 40 or more repeats means a person will develop Huntington’s disease within a normal lifespan, while 36 to 39 carries a reduced, uncertain risk. Counts of 27 to 35 do not cause symptoms but may expand in children, and 26 or fewer is considered normal.
What is the life expectancy with Huntington’s disease?
After symptoms begin, Huntington’s disease typically progresses over about 15 to 20 years, though the range varies. Most deaths result from complications such as pneumonia or injuries from falls rather than the disease itself, which is why supportive care and safety measures are so important.
Sources
- National Institute of Neurological Disorders and Stroke — Huntington’s Disease — NINDS, 2024 — ninds.nih.gov
- Mayo Clinic Staff — Huntington’s Disease: Symptoms and Causes — Mayo Clinic Diseases & Conditions, 2024 — mayoclinic.org
- MedlinePlus, National Library of Medicine — Huntington Disease — MedlinePlus Genetics, 2024 — medlineplus.gov
- Furr Stimming E, Claassen DO, Kayson E, et al. — Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington’s disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial — The Lancet Neurology, 2023 — doi.org/10.1016/S1474-4422(23)00127-8
- McColgan P, Thobhani A, Boak L, et al. — Tominersen in Adults with Manifest Huntington’s Disease — New England Journal of Medicine, 2023 — doi.org/10.1056/NEJMc2300400
- Puig-Davi A, Franch-Marti C, Caler-Gameiro L, et al. — Spontaneous speech and language measures as predictive biomarkers of clinically meaningful disease progression and neurodegeneration in Huntington’s disease — Journal of Neural Transmission, 2026 — doi.org/10.1007/s00702-026-03143-x
Further reading
- Understand the cognitive decline that can develop later in this guide to the memory and thinking changes of dementia.
- Compare Huntington’s chorea with another movement disorder in this guide to the tremor and stiffness of Parkinson’s disease.
- Learn about a mood symptom that often appears early in this guide to the low mood and withdrawal of depression.
- Explore another neurodegenerative condition for comparison in this guide to the progressive memory loss of Alzheimer’s disease.
- Build confidence reading test results with this guide to reference ranges, flags, and next steps on a lab report.
Understand your lab results with BloodSense
Huntington’s disease is confirmed by a precise genetic blood test, and researchers are now studying blood markers of nerve health to follow how it changes over time. Whenever you receive test results, seeing where each value falls against its reference range, and how the numbers connect, makes them far easier to understand and discuss with your care team. BloodSense translates a full lab report into plain language, showing what each marker means and helping you track patterns across visits instead of decoding one result at a time.
